FDA advisory panel backs six of seven peptides, including BPC-157, for the compounding list
REPORTED. FDA’s page confirms a July 23-24, 2026 advisory committee meeting on seven peptides; outlets report the panel supported six of them (including BPC-157) for the 503A bulks list and rejected one. The votes are nonbinding and a formal rule would be needed before pharmacies could compound them.
Attribution: Meeting facts come from FDA’s advisory committee page. The vote results and panel makeup come from AJMC (July 31, 2026) and Michigan Public (July 2026), which we have not independently verified; FDA had posted no outcome on its meeting page when we read it on October 5, 2026.
Allegations in government documents and in reports by others are theirs, not findings by us. Verify against the linked sources. Disclaimer.
By Peptide Industry Gossip · Observed · Published
Status note: This item includes industry discussion, public posts, or submitted tips. It is not an allegation of wrongdoing and should not be treated as verified fact unless specifically marked Documented or Confirmed.
What happened
- On April 16, 2026, FDA announced it would convene the Pharmacy Compounding Advisory Committee to discuss whether certain peptides could be added to the list of bulk substances pharmacies may compound (Foley & Lardner summary of the announcement).
- The committee met July 23-24, 2026 at FDA’s White Oak campus in Silver Spring, MD to discuss seven substances: BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon (FDA meeting page).
- AJMC reports the panel backed six of the seven by narrow margins and rejected emideltide. Michigan Public reports the panel included eight newly appointed members with ties to the peptide industry and quotes one member questioning whether the decision followed market demand rather than science.
- Both outlets say the recommendations are nonbinding. Michigan Public reports a formal rulemaking could stretch into 2028 and that the panel is due to reconvene in February 2027 for more peptides.
What we can verify
- FDA’s page confirms the meeting dates, location, the seven substances and their proposed uses, and docket FDA-2025-N-6895.
- The page lists no vote outcome; materials are posted as downloads.
What remains unknown
- Exact vote counts and panel-member details, which we have not checked against FDA’s posted meeting materials.
- Whether FDA will accept the recommendations, when a proposed rule would appear, and whether any shortcut authority will be used.
- What the outcome means for sellers who label the same peptides research use only; FDA’s warning letters have not changed their stated position.
Timeline
| Date / time | Event |
|---|---|
| 2026-04-16 | FDA announces it will convene the Pharmacy Compounding Advisory Committee to discuss seven peptides. |
| 2026-07-22 | Public comment docket FDA-2025-N-6895 closes. |
| 2026-07-23 | Committee discusses BPC-157, KPV, TB-500 and MOTS-c. |
| 2026-07-24 | Committee discusses emideltide, Semax and Epitalon. |
| 2026-07-31 | AJMC reports the panel backed six of the seven and rejected emideltide. |
| 2026-09-01 | FDA posts warning letters to five peptide sellers that reject “research use only” labeling. |
Participating agencies
| Agency | Reported role or presence |
|---|---|
| FDA Pharmacy Compounding Advisory Committee | Advisory body that votes on whether bulk substances should be on the 503A bulks list. Its votes are nonbinding. |
Receipts
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee · captured 2026-10-05 · tier 1
- Foley & Lardner: FDA to Consider Lifting Restrictions on Numerous Compounded Peptides (May 2026) · captured 2026-10-05 · tier 2
- AJMC: FDA panel backs 6 peptides for compounding (July 31, 2026) · captured 2026-10-05 · tier 2
- Michigan Public: FDA panel considers easing peptide restrictions (July 2026) · captured 2026-10-05 · tier 2
Company response
No company response located as of the publish date.
Why people care
A path for pharmacies to compound BPC-157 and similar peptides would change who can legally sell them and how. The same week-by-week record shows FDA still treating research-use-only sellers as unapproved-drug marketers.
Corrections and update log
No corrections or updates. Request a correction.
Related stories
DOCUMENTED. FDA posted warning letters on Sept. 1, 2026 (dated Aug. 24) to five peptide sellers, stating that products sold as “research use only” are unapproved new drugs. The letters are FDA’s allegations; each firm was told to respond within 15 business days.
DOCUMENTED. FDA posted warning letters on Apr. 7, 2026 (dated Mar. 31) to five peptide sellers, citing unapproved new drug violations; all five letters also name bacteriostatic water sold alongside the peptides. The letters are FDA’s allegations; each firm had 15 working days to respond.
DOCUMENTED. FDA posted warning letters on Dec. 17, 2024 (dated Dec. 10) to four online sellers of research peptides, saying their semaglutide, retatrutide and related products are unapproved new drugs. The letters are FDA’s allegations; each firm had 15 working days to respond.